Fig. 3

The targeted interaction between SNHG6 and miR-135a-5p by complementary binding. a miR-135a-5p expression in blood samples from atherosclerosis patients (n = 32) and healthy donors (n = 20) was examined by RT-qPCR. b The negative correlation between SNHG6 and miR-135a-5p expression in atherosclerosis patients. c HUVECs were treated with different concentrations of ox-LDL (0, 10, 25, 50 µg/ml) for 24 h, then miR-135a-5p expression was measured by RT-qPCR. d Predicted binding sites between SNHG6 and miR-135a-5p, as well as the mutant sites in SNHG6-MUT reporter. e HEK293T cells were co-transfected with miR-135a-5p mimic or miR-NC mimics together with GAS5-WT or GAS5-MT reporter, followed by the detection of luciferase activity in each group. f RIP assay was carried out to examine the enrichment levels of SNHG6 and miR-135a-5p in IgG or Ago2 immunoprecipitation complex. g HUVECs were transfected with SNHG6, si-SNHG6#1, si-SNHG6#2, or relative control, and then miR-135a-5p level was tested by RT-qPCR. h HUVECs were transfected with miR-135a-5p mimics, miR-135a-5p inhibitors, or relative control, and then SNHG6 level was measured by RT-qPCR. *P < 0.05 and **P < 0.01; ^## P < 0.01